How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Blood Glucose Monitoring Consumables Market
- By Product Type: Test Strips, Lancets, Control Solutions, Alcohol Swabs, Meter Cases
- By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Laboratories
- By Technology: Electrochemical Test Strips, Optical Test Strips, Enzymatic Test Strips
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Sales
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Test Strips leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.163 →
- 11 Company Profiles 17 players: SWOT & benchmarking p.171 →
Full report · locked preview
Everything inside the Blood Glucose Monitoring Consumables Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
End User 4
Technology 3
Distribution Channel 4
Companies profiled
Roche Diagnostics
Abbott Laboratories
Dexcom Inc.
Medtronic plc
Ascensia Diabetes Care (a Panasonic Healthcare company)
LifeScan
Inc. (a Johnson & Johnson company)
Bayer AG
Arkray Inc.
Nipro Corporation
Terumo Corporation
Sinocare Inc.
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Dexcom Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Ascensia Diabetes Care (a Panasonic Healthcare company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →LifeScan
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Inc. (a Johnson & Johnson company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Bayer AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Arkray Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Nipro Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Terumo Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sinocare Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →A. Menarini Diagnostics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →F. Hoffmann-La Roche Ltd
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Trividia Health Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Agamatrix
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →
Global · 2025–2033
$9,728M by 2033 · 9.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Test Strips33.7
- Lancets13.2
- Control Solutions11.1
- Alcohol Swabs22.1
- Meter Cases19.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,601M → $3,286M · 9.4%
Europe$1,116M → $2,470M · 10.4%
Asia Pacific$1,019M → $2,195M · 10.1%
Latin America$630.8M → $1,421M · 10.7%
Middle East and Africa$485.2M → $1,024M · 9.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.042026
9.052027
9.072028
9.062029
9.082030
9.102031
9.112032
9.112033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche Diagnostics21.4
- Abbott Laboratories18.6
- Dexcom Inc.7.2
- Medtronic plc6.0
- Ascensia Diabetes Care (a Panasonic Healthcare company)10.9
- LifeScan8.0
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type30.9%
End User27.5%
Technology19.6%
Distribution Channel22.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.6
- Europe23.8
- Asia Pacific21.1
- Latin America13.7
- Middle East and Africa9.8
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche Diagnostics | 91 | 73 | 76 | 93 | 82 | 91 | 84 |
| Abbott Laboratories | 76 | 84 | 75 | 82 | 81 | 82 | 80 |
| Dexcom Inc. | 83 | 86 | 68 | 74 | 66 | 83 | 77 |
| Medtronic plc | 59 | 77 | 62 | 74 | 76 | 76 | 71 |
| Ascensia Diabetes Care (a Panasonic Healthcare company) | 74 | 51 | 60 | 67 | 73 | 59 | 64 |
| LifeScan | 51 | 53 | 48 | 66 | 69 | 50 | 56 |
| Inc. (a Johnson & Johnson company) | 61 | 43 | 50 | 58 | 66 | 52 | 55 |
| Bayer AG | 43 | 46 | 57 | 42 | 60 | 37 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche Diagnostics
- Abbott Laboratories
- Dexcom Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche Diagnostics | ✓ | ✓ | − | ◐ | ✓ | ✓ |
| Abbott Laboratories | ◐ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Dexcom Inc. | ◐ | ✓ | ◐ | ✓ | − | ✓ |
| Medtronic plc | − | ✓ | ◐ | − | ◐ | ✓ |
| Ascensia Diabetes Care (a Panasonic Healthcare company) | ◐ | ◐ | ◐ | − | ✓ | ◐ |
| LifeScan | ◐ | − | − | − | ◐ | − |
| Inc. (a Johnson & Johnson company) | ◐ | − | ◐ | ◐ | ◐ | ◐ |
| Bayer AG | − | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche Diagnostics84
2Abbott Laboratories80
3Dexcom Inc.77
4Medtronic plc71
5Ascensia Diabetes Care (a Panasonic Healthcare company)64
6LifeScan56
7Inc. (a Johnson & Johnson company)55
8Bayer AG48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Roche DiagnosticsAbbott Laboratories
Challenger2
Strong scale, closing on the leaders.
Dexcom Inc.Medtronic plc
Contender1
Focused players with pockets of strength.
Ascensia Diabetes Care (a Panasonic Healthcare company)
Niche3
Specialists in a single segment or region.
LifeScanInc. (a Johnson & Johnson company)Bayer AG
Go-to-market strategy
Land Product Type in North America, then scale across Blood Glucose Monitoring Consumables Market — a $504M beachhead inside a $8.78B market.
Beachhead (SOM)$504Mobtainable near-term
Serviceable (SAM)$3.59Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Test Strips
Best fit — highest urgency & budget in Product Type.
Economic buyer76 fit
Lancets
Strong fit — clear ROI and a fast path to value.
End user67 fit
Control Solutions
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel29%
Digital / self-serve21%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Blood Glucose Monitoring Consumables Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified25%
Evaluation15%
Closed-won6%
$12.7KCAC
$71KLTV
5.6:1LTV : CAC
< 3 moCAC payback
Investment thesis
Blood Glucose Monitoring Consumables Market is a resilient opportunity — $2.95B by 2033, compounding at 5.2%.
TAM · 2025$1.96Btoday
TAM · 2033$2.95Bforecast
CAGR5.2%2027–2033
Cumulative$21.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.95BTotal addressable market
SAM$1.21BServiceable available market
SOM$208MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.2% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.95BLarge & growingTAM by 2033 at 5.2% CAGR
$1.21BServiceable nowreachable with today’s model
$208MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.30BBear3.4% CAGR
$2.95BBase5.2% CAGR
$3.77BBull6.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Blood Glucose Monitoring Consumables Market — a $4.21B market by 2033. Plan: grow share from 9.0% to 16.9%.
Market size · 2033$4.21Btotal addressable
Market CAGR5.1%2027–2033
Target share16.9%from 9.0% today
Revenue ambition$711Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.0% | 16.9% | At risk |
| Revenue | $352M | $711M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 32.5% | 43.9% | At risk |
| Customer retention | 87.3% | 93.3% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $77M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Sales deck · value proposition
Win the Blood Glucose Monitoring Consumables Market conversation — a $1.47B market you can size, segment and defend in minutes.
Market size · 2033$1.47Btotal opportunity
Growth4.6%CAGR to 2033
Addressable buyers1,744+accounts in scope
Typical ROI4.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.7×return on cost, year one
< 3 mopayback period
$50K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Roche DiagnosticsAbbott LaboratoriesDexcom Inc.Medtronic plcAscensia Diabetes Care (a Panasonic Healthcare company)LifeScanInc. (a Johnson & Johnson company)Bayer AG+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Blood Glucose Monitoring Consumables Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Blood Glucose Monitoring Consumables Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Blood Glucose Monitoring Device Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportBlood Glucose Monitoring System (BGMS) Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportBlood Glucose Monitoring Systems Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportBlood Glucose Sensor Patch Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportBlood Glucose Sensors Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportBlood Glucose Strip Market
Market size, share, segmentation and regional forecast.
$516M market · 2025 base year
View reportBlood Glucose Test Meter Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportBlood Glucose Testing Device Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportBlood Glucose Testing System Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportBlood Glucose Therapy System Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportBlood Lancets Market
Market size, share, segmentation and regional forecast.
$514M market · 2025 base year
View reportBlood Lipid Meter Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.